**What's Known**

-   Almost all sulfur mustard (SM) victims suffer from delayed complications of this poisoning. These patients receive supportive and symptomatic treatments based on a decision by the physicians

-   To date, there has been no standard treatments for these patients.

**What's New**

-   A narrative review of recently approved treatment protocols by ophthalmologists, dermatologists, and pulmonologists who were involved in clinical management of SM victims.

-   Leveraging on Professor Balali-Mood's extensive experience in treating the veterans of the Iraqi SM attack, his continuous research, and clinical management of patients.

Introduction {#sec1-1}
============

In the first part of this paper, we comprehensively reviewed the toxicity mechanisms of sulfur mustard (SM) and the delayed complications of SM (DCSM) in different organs of the body with a particular reference to Iranian veterans. In this part, we aim to review and discuss recent protocols recommended for DCSM treatment.

Since there is still no approved antidote for sulfur mustard (SM) poisoning, clinical management of DCSM exposure on different organs of pulmonary, skin, ocular, neuro-psychiatric, immune, and cardiovascular systems are supportive and symptomatic ([table 1](#T1){ref-type="table"}). Therefore, most patients with DCSM receive several medicines which might put them at the risk of drug-drug interaction and/or adverse drug reactions.

###### 

Recommended treatment for the delayed complications of sulfur mustard

  ------------------------------------------- ----------------------------------------------------------------
  Ocular                                      Artificial tears
  Tear-duct plugs                             
  Therapeutic contact lenses                  
  Amniotic membrane transplantation           
  Temporary or permanent punctual plug        
  Blepharorrhaphy                             
  Tarsorrhaphy                                
  Limbal stem cell transplantation            
  Corneal transplantation                     
  Topical steroids (in relapse episode)       
  Immunosuppressive (if need)                 
  Respiratory                                 Annual evaluation by PE, PFT, CXR, and tuberculin skin testing
  Respiratory physiotherapy rehabilitations   
  Mucolytic agents (NAC)                      
  Warm humidified air                         
  Long-acting b2-agonists                     
  Inhaled corticosteroids                     
  Cancer screening programs                   
  Skin                                        Reduce taking shower and bath
  Topical corticosteroids                     
  Systemic antihistamines                     
  Sunscreen compounds                         
  ------------------------------------------- ----------------------------------------------------------------

NAC: N-acetyl cysteine; PE: Physical exams; PFT: Pulmonary function tests; CXR: Chest radiography

Iranian researchers of various specialties (e.g. ophthalmologists, pulmonologists, dermatologist) who have been involved in treating long-term effects and delayed complications of SM veterans have recently published national treatment protocols. Here, it is aimed to review the protocols and recent advances of long-term treatment of delayed complications of SM poisoning to find the best and the optimum solution for the veterans. This review has already been published as a chapter of a book on mustard compounds.^[@ref1]^

*Management of Ocular Complications* {#sec1-2}
------------------------------------

As for other DCSM, management of delayed ocular complications of SM (DOCS) is supportive and almost all require long-term follow-up to control the symptoms and signs such as dryness, feelings of granulation, itching, burning sensation; photophobia, tearing, ocular pain, chronic conjunctivitis; peri-limbal hyperpigmentation, corneal thinning, vascular tortuosity, limbal ischemia; corneal opacity, corneal vascularization, and corneal epithelial defect.^[@ref1]-[@ref4]^

Recommended supportive treatments for eye dryness, a common symptom of DOCS, are preservative-free artificial tears, tear-duct plugs, and some types of contact lenses.^[@ref3],[@ref5]-[@ref8]^ Keratitis due to DOCS can be controlled by repairing ocular surface instability and tearing deficiency.^[@ref1]^ Depending on the severity of keratitis, the following treatments are applied: preservative-free artificial tears, immunosuppressive, and therapeutic contact lenses.^[@ref1]^ Some suggest surgical interventions for DOCS include amniotic membrane transplantation, temporary or permanent punctual plugs, surgical repair of the eyelid (blepharorrhaphy); tarsorrhaphy, transplantation of direct family members' limbal stem cell, and corneal transplantation.^[@ref6],[@ref9]^ Following allogeneic transplantations, immunosuppressive therapy is required to prevent rejection.^[@ref6]-[@ref9]^ Episodes of relapsed inflammation can be managed by topical steroids;9 however, continuous administration of topical steroids is forbidden due to complications as a result of its long-term use (e.g. glaucoma, cataracts, and increased risk of infection).^[@ref3],[@ref9],[@ref10]^ In severe cases, systemic corticosteroids are administrated especially when topical steroids are ineffective. If both types of corticosteroids (topical and systemic) fail to control inflammation of limbus or cornea, systemic immunosuppressives such as azathioprine and cyclosporine A are indicated.^[@ref9]^

The effect of primary ocular treatment on the frequency of DOCS is doubtful. We could not find any research that compared DOCS of veterans treated by various regimens. However, most authors believe that the quality of early treatment is effective on the frequency of DOCS. However, they do not recommend any consensus treatment plan. There are some reports on animal studies on DOCS. The treatment of SM intoxicated rabbits by topical ophthalmic solution of dexamethasone or diclofenac erased early clinical symptoms and revealed severe damage to the cornea, but both regimens could not alleviate corneal erosions and revealed only a short delay in epithelial regeneration ([table 2](#T2){ref-type="table"}). ^[@ref11]-[@ref15]^ Long-term treatment with topical doxycycline in SM intoxicated rabbits reduced metalloproteinases activity, as inflammatory index^[@ref16]^ in the tear fluid. Moreover, not only it reduced the acute injury but was also suggested as a preventive therapy for ameliorating the DOCS. However, researchers believed that doxycycline was only effective in the pre-neovascularization stage.^[@ref16]^ .

###### 

Suggested treatment for delayed ocular complications of sulfur mustard (SM) by different authors

  First author^(reference)^                           Design                                 Precipitants                                  Evaluation                                        Result
  --------------------------------------------------- -------------------------------------- --------------------------------------------- ------------------------------------------------- -----------------------------------------
  Amir^[@ref11]^                                      SM (390 mg/L for 2 min)                Rabbit                                        Clinical symptoms                                 Dexa and Dic were effective
  SM+Dexa (x4/d)                                      TP and PGE of AC                       Dexa=Dic\<\<SM                                                                                  
  SM+Dic (x4/d)                                       Cellular infiltration of cornea        Dexa=Dic\<\<SM                                                                                  
  Corneal erosions                                    Both were not effective                                                                                                                
  Epithelial regeneration                             A short delay                                                                                                                          
  Gonzalez^[@ref12]^                                  Diltiazem (10 mM) pretreatment to NM   Rabbit                                        Intraocular pressure                              Reduced (effective)
  Pupil diameter                                      Not effective                                                                                                                          
  Palpebral closure                                   Attenuated                                                                                                                             
  Conjunctival symptoms                               Reduced and delayed (effective)                                                                                                        
  TP of AC                                            Not effective                                                                                                                          
  Gross^[@ref13]^                                     DLSP pretreatment to SM                Human epidermal keratinocytes                 GST level                                         Not effective
  Survival                                            Not effective                                                                                                                          
  Glutathione level                                   Not effective                                                                                                                          
  Horwitz^[@ref14]^                                   Doxycycline (2 mg/ml) x4/d             Rabbit                                        MMP-9 and 2 in tear and cornea                    Reduced (effective)
  Javadi^[@ref15]^                                    Retrospective, case series:            99 veterans with delayed-onset SM keratitis   The clinical outcomes and graft survival rates.   The rejection-free graft survival rate:
  Limbal stem cell transplantation: lrCLAL vs. KLAL   lrCLAL=39.1% vs. KLAL=80.7%                                                                                                            
  Corneal transplantation techniques: PK vs. Lk       PK=39.0% vs. LK=90.3%                                                                                                                  

x4/d: Four times a day; AC: Anterior chamber; Dexa: Dexamethasone; Dic: Diclofenac; DLSP: DL sulforaphane; GST: Glutathione S transferases; KLAL: Keratolimbal allograft; Lk: Lamellar keratoplasty; lrCLAL: Living related conjunctival limbal allograft; MMP: Matrix metalloproteinases; NM: Nitrogen mustard; PGE: Prostaglandin E; PK: Penetrating keratoplasty; TP: Total protein

BO: Bronchiolitis obliterans; CGRP: Calcitonin gene related peptide; CPET: Cardiopulmonary exercise test; DRCS: Delay respiratory complications of SM; FEV1: Forced expiratory volume in 1 S; FVC: Forced vital capacity; IL: Interleukin; INFG: Interferon gamma; MDA: Malondialdehyde; MMEFR: Maximal mid expiratory flow rate 25% 75%; MMP: Matrix metallopeptidase; NAC: N acetyl cysteine; PEFl: Peak expiratory flow,; PEFo: Peak expiratory force; PFT: Pulmonary function test; PR: Pulmonary rehabilitation 30 minutes/2 times a week; Reversibility: 10% increase of FEV1 in the 2nd month; RV: Residual volume; TGF: Transforming growth factor; TLC: Total lung capacity; TNF: Tumor necrosis factor

Corneal argon laser photocoagulation was not quite successful in controlling corneal vascularization. ^[@ref9],[@ref15],[@ref17],[@ref18]^ Penetrating keratoplasty (PK) was applied for chronic and delayed mustard gas keratitis (table 2). A follow-up of DOCS patients who underwent PK revealed that about 22% of the grafts failed, and nearly 60% of subepithelial or endothelial grafts were rejected. Due to the limitation of the limbal blood supply of SM veterans, this type of keratoplasty has not shown effective results and has a poor prognosis in DOCS.^[@ref9],[@ref15],[@ref17],[@ref18]^ However, the follow-up of DOCS patients who underwent lamellar keratoplasty (LK) and keratolimbal allograft (KLAL) had a better long-term prognosis and these methods were suggested for long-term corneal and limbal complications of SM.^[@ref15]^

*Management of Respiratory Complications* {#sec1-3}
-----------------------------------------

Delayed respiratory complications of SM (DRCS), unlike ocular complication, had no asymptomatic phase. SM intoxicated patients suffered from a continually progressive pulmonary complication that started from the initial exposure.3 DRCS are the most common causes of a long-term disability of SM intoxicated victims, 1 and adversely affect patients' quality of life.^[@ref19]^ Nearly all of the moderate to severe SM victims suffered from some degrees of DRCS.^[@ref20]^ DRCS are present in various types: chronic obstructive pulmonary disease (COPD) (35%), bronchiectasis (32.5%), asthma (25%); large airway narrowing (15%), pulmonary fibrosis (7.5%), and simple chronic bronchitis (5%).^[@ref20]^ DRCS patients with COPD have a greater reduction of FEV1 per year; consequently, they had a worse prognosis than non-SM COPD patients.^[@ref21]^

The protocol for the management of DRCS, as shown in [table 1](#T1){ref-type="table"}, includes reducing restrictions and stenosis caused by scarring and trying to reverse the reversible obstructive airways by inhaled corticosteroids and long-acting b2-agonists.^[@ref3]^ Also, frequent physical examination and if required chest radiography, pulmonary function tests, and tuberculin skin test should be performed to evaluate the progression of DRCS. Additionally, the patients should be monitored for early detection and treatment of cancer, infections, or exacerbation.^[@ref3]^ Although there are several suggested protocols for the treatment of DRCS patients, individual variations may be involved because of the genetic tendency, underlying diseases, health status, the duration and frequency of exposure to SM; emergent and follow-up medical care, smoking, exposures to other pulmonary irritating compounds, and different types of DRCS. Therefore, physicians should select the treatment on a case-by-case basis.^[@ref22]^

Respiratory physiotherapy rehabilitations that include postural drainage of sputum and percussion and vibration of the chest wall, during deep breathing and voluntary coughing, are important medical modalities in the treatment of DRCS ([table 1](#T1){ref-type="table"}).^[@ref22]^ This manipulation also improves the spirometric parameters.^[@ref23]^ There is no suggestion on any special respiratory physiotherapy for DRCS patients and it is applied similar to other chronic pulmonary diseases.^[@ref1]^

Warm humidified air and various types of mucolytic agents such as N-acetyl cysteine (NAC) are recommended for the treatment of DRCS ([table 1](#T1){ref-type="table"}).^[@ref24]^ NAC with both antioxidant and mucolytic properties can improve the pulmonary function tests, quality of life, and reduce bronchial infections and exacerbations ([table 2](#T2){ref-type="table"}).^[@ref25]^ NAC also affects the fibrozing alveolitis of patients with DRCS,^[@ref24]^ similar to other COPD patients, as it reduces the release of inflammatory mediators. ^[@ref1]^

Ghanei et al.^[@ref25]^ (2008) treated 144 DRCS patients with NAC (1,200 mg daily) or placebo for 4 months ([table 3](#T3){ref-type="table"}).^[@ref19],[@ref21],[@ref25]-[@ref33]^ All patients had SM-induced bronchiolitis obliterans. The NAC treated group showed a significant improvement in dyspnea, wake-up dyspnea, cough, spirometric components, and reduced sputum compared to the control group. NAC also reduced their oxidative stress and inflammatory response. In another study, Shohrati et al.^[@ref30]^ (2008) reported that 4 months treatment of DRCS patients with 1,800 mg daily NAC, improved their clinical conditions and spirometric parameters ([table 3](#T3){ref-type="table"}).

###### 

Suggested treatment for delayed respiratory complications of sulfur mustard (SM) by different authors

  First author ^(reference)^                                                                       Precipitants/design                                                                                            Evaluation                                                                               Results
  ------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- -----------------------------------------
  Abtahi^[@ref21]^                                                                                 BO (n=16): Seretide 125-250/25 (2 puffs BID)+Azithromycin (250 mg, three times/week)+NAC (1200-1800 mg/day).   5 years PFT indices:                                                                     
  Asthma (n=38), COPD (n=16): Existing guidelines                                                  Basal and final FEV1                                                                                           BO=COPD                                                                                  
  Yearly FEV1 decline                                                                              BO=COPD                                                                                                                                                                                                 
  Ghanei^[@ref26]^                                                                                 Randomized clinical trial, 12 weeks on 105 DRCS patients                                                       FEV1, FVC, FEV1/FVC%, and PEFo                                                           Increased:
  Group 1 (n=52): Fluticasone propionate 500 µ/day+Salmeterol 100 µ/day                            Reversibility                                                                                                  Group 1\>Group 2                                                                         
  Group 2 (n=53): Beclomethasone 1000 µ/day+Salbutamol 800 µ/day                                   Group 1\>Group 2                                                                                                                                                                                        
  Panahi^[@ref19]^                                                                                 15 DRCS patients                                                                                               Quality of life, FEV1                                                                    Improved
  INFG (100 µg) every other day for 6 months                                                       Cough, dyspnea, sputum, hemoptysis                                                                             Decreased                                                                                
  Serum levels of IL-2, 4, 6, 10, CGRP, MMP-9, TNF-alpha, TGF-beta, and MDA                        Decreased                                                                                                                                                                                               
  INFG, total and reduced glutathione                                                              Increased                                                                                                                                                                                               
  Shohrat^[@ref27]^                                                                                3 groups (n=18) of DRCS patients                                                                               Cough and nocturnal dyspnea                                                              Group 1\<Group 3
  Group 1: Serevent+Flixotide+PR+Tiotropium bromide 18 µg/day                                      FVC, MMEFR, and PEFl                                                                                           Group 1\>Group 2                                                                         
  Group 2: Serevent+Flixotide+PR                                                                   FEV1                                                                                                           Group 1\<Group 2                                                                         
  Group 3: PR                                                                                      CPET                                                                                                           Group 1=2 = 3                                                                            
  Ghanei^[@ref28]^                                                                                 Methylprednisolone (500 mg/ day on days 1-3 and 250 mg /day on days 4-6)                                       PFT indices on admission and on day 8 of therapy                                         Group 1=Group 2
  Ghanei^[@ref29]^                                                                                 17 DRCS patients (non-responsive to conventional treatments)                                                   Cough and sputum, FEV1 and FVC                                                           Improved
  Clarithromycin+NAC for 6 months                                                                  FEV1/FVC                                                                                                       No significant change                                                                    
  Shohrati^[@ref30]^                                                                               144 DRCS, BO classes 1 and 2, Placebo double-blind clinical trial                                              Dyspnea, wake-up dyspnea, cough, and sputum after 4 months                               Improved
  Group 1 (n=72): NAC 1,800 mg/day 2-4 months                                                      PFT indices after 4 months                                                                                     Improved                                                                                 
  Group 2 (n=72): Placebo                                                                                                                                                                                                                                                                                  
  Ghanei^[@ref25]^                                                                                 144 DRCS, BO classes 1 and 2, Placebo double-blind clinical trial                                              Dyspnea, wake-up dyspnea, cough, and sputum after 4 months                               Improved
  Group 1 (n=72): NAC 1200 mg/day 2-4 months                                                       PFT indices after 4 months                                                                                     Improved                                                                                 
  Group 2 (n=72): Placebo                                                                                                                                                                                                                                                                                  
  Boskabady^[@ref31]^                                                                              40 DRCS patients for 2 months                                                                                  Wheezing                                                                                 Improved
  Study group (n=20): 0.375 mL/kg of nigella seed boiled extract                                   Respiratory symptom score                                                                                      Improved                                                                                 
  Control group (n=20): Placebo                                                                    PFT values                                                                                                     Improved                                                                                 
  Panahi[@ref32]                                                                                   36 DRCS patients                                                                                               FEV1                                                                                     Improved
  Study group (n=18): IFNG-1b (200 µg three times per week)+Prednisolone 7.5 mg/day for 6 months                                                                                                                                                                                                           
  Control group (n=18): Prednisolone 7.5 mg/day+Salbutamol+Beclomethasone                                                                                                                                                                                                                                  
  Ghanei[@ref33]                                                                                   Noninvasive positive-pressure ventilation                                                                      Systolic blood pressure, Mean arterial pressure, Pulse rate, Respiratory rate, Dyspnea   Decreased in study group\>Control group
  Study group (n=12): 79:21 helium: oxygen                                                         Oxygen saturation, Diastolic blood pressure                                                                    Increased in study group=Control group                                                   
  Control group (n=12): 79:21 air: oxygen                                                                                                                                                                                                                                                                  

BO: Bronchiolitis obliterans; CGRP: Calcitonin gene related peptide; CPET: Cardiopulmonary exercise test; DRCS: Delay respiratory complications of SM; FEV1: Forced expiratory volume in 1 S; FVC: Forced vital capacity; IL: Interleukin; INFG: Interferon gamma; MDA: Malondialdehyde; MMEFR: Maximal mid expiratory flow rate 25% 75%; MMP: Matrix metallopeptidase; NAC: N acetyl cysteine; PEFl: Peak expiratory flow,; PEFo: Peak expiratory force; PFT: Pulmonary function test; PR: Pulmonary rehabilitation 30 minutes/2 times a week; Reversibility: 10% increase of FEV1 in the 2nd month; RV: Residual volume; TGF: Transforming growth factor; TLC: Total lung capacity; TNF: Tumor necrosis factor

Salbutamol (a beta agonist) and ipratropium bromide (an anticholinergic) in the form of inhaler have been applied for DRCS patients to achieve a better lung function and reduce the airway hyper-reactivity.^[@ref1],[@ref34],[@ref35]^ Mehrtash (2002) compared pulmonary function tests after the administration of salbutamol spray alone or in combination with ipratropium bromide in SM veterans. He reported a more remarkable effect, 3 hours later, using the combination therapy compared to single therapy.^[@ref36]^ Ghanei et al. (2007) reported that the combination of inhaled corticosteroids, beclomethasone or fluticasone propionate, long-acting β2-agonists, and salmetrol were effective in the management of chronic bronchiolitis of DRCS patients ([table 3](#T3){ref-type="table"}).^[@ref26]^

One important mechanism of both the progression and exacerbation of DRCS is inflammation that includes the accumulation of inflammatory cells in the respiratory tract and the production of inflammatory mediators.^[@ref1]^ Inflammation probably plays an important role in the airway obstruction of DRCS and thus several anti-inflammatory agents are suggested for the treatment of lung problems. It is reported that NSAID may be effective in DRCS.^[@ref1]^

Corticosteroids have a potent anti-inflammatory property. They are recommended more by inhalation than by systematic route. However, the long-term administration of inhaled corticosteroids do not augment the survival time of DRCS patients, and only have an effect on quality of life.1 There is an impression that DRCS are not the neutrophil dominated inflammatory disease and are an eosinophilic inflammation; thus, oral corticosteroids could not have a great effect.^[@ref37]^ However, oral corticosteroids are usually advised to patients with respiratory exacerbation. ^[@ref1]^ Therefore, oral corticosteroids should be reserved for severe and unresponsive to inhaled corticosteroids cases.^[@ref1]^

Ghanei et al. (2005) compared pulse therapy, tapered doses of intravenous methylprednisolone acetate (500 mg/day on days 1-3 and 250 mg/day on days 4-6), and oral therapy of corticosteroids, prednisolone. They found no difference in patients' response. Nevertheless, both groups had a better pulmonary function than their own controls ([table 3](#T3){ref-type="table"}).^[@ref28]^

Osteopenia and reduction in bone mineral density (BMD) may result in a systemic absorption of high-dose inhaled corticosteroids through the lung parenchyma.^[@ref38]^ Attaran et al. (2007) compared the BMD of 35 SM veterans, treated by beclomethasone dipropionate or fluticasone dipropionate 300-1000 μg/day, with 75 normal individuals for 3-15 years. They reported that BMD in the femoral region has a negative correlation with the severity of bronchial obstruction, but not in the lumbar region. Also, they described a decrease in BMD secondary to long-term therapy with inhaled corticosteroids.^[@ref39]^

Abtahi et al. (2016) followed up 73 DRCS patients (asthma: 38, COPD: 16, and bronchiolitis obliterative (BO): 19) for 5 years. They treated BO patients with NAC (1,200-1,800 mg/day), inhaled Seretide 125-250/25 (2 puffs BID), and azithromycin (250 mg, three times/week). The other two groups were treated with existing guidelines. They found no significant differences between the basal, final, and yearly decline of FEV1 of BO and COPD patients. Therefore, they recommended therapeutic regimen for BO patients of DRCS ([table 3](#T3){ref-type="table"}).^[@ref21]^

The level of transforming growth factor β1 (TGF-b1) in bronchoalveolar lavage and pulmonary samples of DRCS patients were higher than in normal persons and resembled pulmonary fibrosis patients.^[@ref40]^ TGF-beta molecule and receptors have been over-expressed in primary airway fibroblasts of SM veterans.^[@ref41]-[@ref43]^ Therefore, it seems that TGF-b1 has a fundamental role in the pathogenesis of DCRS, and the treatment of DRCS patients with interferon-gamma (IFN-γ) (i.e. able to reduce TGF-β) may be effective. IFN-γ has shown favorable effects on adjusting cytokines, modifying oxidative stress, improving respiratory symptoms, and the quality of life of DRCS ([table 3](#T3){ref-type="table"}). ^[@ref19],[@ref44]^

In patients with SM lung injuries, neutrophilic (non-eosinophilic) inflammation is predominant. Thus, macrolide antibiotics can play an anti-inflammatory role by modulating the production of pro-inflammatory cytokines and mediators, and improve macrophage functions.^[@ref37],[@ref45]^ Gao (2008, 2010) evaluated different macrolides (roxithromycin, clarithromycin, azithromycin, and erythromycin) on phagocytotic and chemotactic of SM treated monocyte and the production of various inflammatory cytokines/mediators. Reduced chemotaxis and phagocytosis of SM treated monocyte were restored by all types of macrolides. Also, over-expressed inflammatory cytokines and over-stated nitric oxide (NO) production, induced by SM, were reduced up to 70% by the antibiotics. Therefore, they suggested that treatment with macrolide can enhance clearance of apoptotic material in the airway and leads to the reduction of airway inflammation.^[@ref45],[@ref46]^ Ghanei et al. (2008) reported that adding azithromycin to the protocol of DRCS patients who have not responded to full dose prednisone is not effective.^[@ref47]^ However, according to the results of another clinical trial, they recommended 6 months treatment with clarithromycin and NAC to reduce chronic bronchitis and bronchiolitis of DRCS patients ([table 3](#T3){ref-type="table"}).^[@ref29]^

Oxidant versus antioxidant balance has an important role in DRCS pathogenesis.^[@ref30],[@ref48]^ Thus, antioxidants were evaluated in the treatment of DRCS. Compared to the placebo control group, 45 DRCS patients who received combined curcuminoids (1,500 mg/day) and piperine (15 mg/day) for a period of 4 weeks had higher glutathione and lower malonedialdehyde concentration at the end of the trial. More tolerable signs and symptoms based on COPD assessment scoring tests were reported.^[@ref49]^ The curcuminoids+piperine treated patients had better FEV1/FVC and lower inflammatory mediators, including interleukins 6 and 8, tumor necrosis factor-alpha, transforming growth factor-beta; high-sensitivity C-reactive protein, calcitonin gene-related peptide, and substance P.^[@ref50]^

Magnesium ion is effective in asthmatic patients as a bronchodilator because of relaxing the smooth muscles of the respiratory system.^[@ref51]^ It also stabilizes mast cells that released bronco-constrictor mediators, thus it decreases bronchial responsiveness of the bronchial tree.^[@ref1],[@ref52]-[@ref54]^

SM can induce pulmonary artery hypertension.^[@ref55]^ Sildenafil is a phosphodiesterase type 5 inhibitor that relaxes vascular smooth muscles (vasodilatation) through increasing nitric oxide contents. It is approved for the treatment of pulmonary artery hypertension and can be used for reducing pulmonary artery pressure of DRCS.^[@ref24],[@ref55]^

Bayat et al. (2006) evaluated the effect of Thymus vulgaris extract (oral drop 2%) on dyspnea, cough, amount of sputum, and spirometric parameters. They concluded that this compound had a significant effect on veterans signs and symptoms.^[@ref56]^

The preventive effect of Nigella sativa on tracheal responsiveness and lung inflammation of SM intoxicated guinea pigs has been reported.^[@ref57],[@ref58]^ Because of anticholinergic and antihistaminic effects of Nigella sativa seed, Boskabady (2011) evaluated bronchodilator and anti-inflammatory effects of Nigella sativa seed on 40 DRCS patients in a randomized, double-blind, placebo-controlled trial for 2 months. They reported improvement in all respiratory symptoms, chest wheezing, and pulmonary function tests values in the Nigella sativa seed treated group.^[@ref31]^

Ghanei et al. (2011) evaluated circulatory and pulmonary criteria of DRCS patients, treated with acute respiratory decompensation by 79:21 helium: oxygen inhaled through non-invasive positive-pressure ventilation in comparison with 79:21 air: oxygen. The helium: oxygen treated group had a higher reduction in systolic, diastolic and mean arterial pressure, pulse rate, respiratory rate and dyspnea; and had also a higher arterial oxygen saturation than the air: oxygen treated group.^[@ref33]^

The recommended treatments for SM lung exacerbation have resemblance to other COPD exacerbations. Inhaled corticosteroids or brief time systemic corticosteroids, oxygen supplement therapy, mucolytics; chest physiotherapy, appropriate antibiotics, and morphine are components of the treatment.^[@ref24]^ Ghanei recommended oral or intravenous corticosteroids in DRCS exacerbation and in un-responded patients; IFN-γ is added to the regimen.^[@ref59]^

*Management of Skin Complications* {#sec1-4}
----------------------------------

Reported delayed cutaneous complications of SM (DCCS) includes itching, hyper and hypopigmentation, dermal scarring; dry skin, multiple cherry angiomas, and atrophy.^[@ref60]^ The management of almost all DCCS are supportive and symptomatic ([table 1](#T1){ref-type="table"}).^[@ref1]^

Itching is the most common symptom of DCCS.^[@ref3],[@ref5],[@ref61]-[@ref63]^ Patients should avoid frequent showering and bathing.^[@ref1]^ However, topical corticosteroids and systemic antihistamines are the standard treatment for skin itching ([table 1](#T1){ref-type="table"})^[@ref1]^ and skin atrophy is a side effect of prolonged use of corticosteroids. The adverse effect depends on the type of corticosteroids, the vehicle, and the location of its application.^[@ref3]^ Other adverse effects of prolonged use of corticosteroids include the exacerbation of skin infections, rosacea, acne, striae; purpura, dyspigmentation, and perioral dermatitis. Systemic reactions such as hyperglycemia, glaucoma, adrenal insufficiency, and delayed wound healing have been reported following the long-term application of topical corticosteroids.^[@ref64]^

Due to the adverse effects of the long-term application of corticosteroids, several compounds are evaluated and suggested for controlling the itching of DCCS. Panahi et al. (2008-2012) compared betamethasone cream 0.1% versus capsaicin cream 0.025%, pimecrolimus, IFN-γ 50 μg/m^2^, and Aloe vera/olive oil cream in Iranian veterans with DCCS in four distinct clinical trials ([table 4](#T4){ref-type="table"}).^[@ref65]-[@ref74]^ Capsaicin reduced the scaling of pruritus and skin dryness less than betamethasone, but the burning sensation in the capsaicin-treated group was higher than the controls and 35% of the patients suffered from a burning sensation and its intolerable odor.^[@ref71]^ Pimecrolimus is an inhibitor of T-cell activation by the calcineurin pathway and reduces the release of numerous inflammatory cytokines. It is used in the treatment of atopic dermatitis (eczema). Pimecrolimus reduced pruritus score, burning sensation, and skin dryness as much as betamethasone. The severity of vesicle, hypo- and hyper-pigmentation, erythema, lichenification, fissure, and excoriation did not change by pimecrolimus or betamethasone administration.^[@ref70]^ A trial has shown that Aloe vera/olive oil cream was as effective as betamethasone in controlling the pruritus, burning sensation, and skin dryness. Nevertheless, excoriation and fissure were only reduced by Aloe vera/olive oil cream. Aloe vera and/or betamethasone could not change erythema, blisters, hypo- and hyper-pigmentation lesions and lichenification of the skin of DCCS patients ([table 4](#T4){ref-type="table"}).^[@ref68]^ Hydrophilic decontamination formulation of CC-2 (DRDE/WH-03) that was fortified with Aloe vera gel has shown appropriate wound healing efficacy in mice model.^[@ref75]^ .

###### 

Suggested treatment for delayed cutaneous complications of sulfur mustard by different authors

  First author^(reference)^                                        Design                      Evaluation                            Results
  ---------------------------------------------------------------- --------------------------- ------------------------------------- ----------------------------
  Panahi^[@ref65]^                                                 6-week RDBCT, 80 DCCS       Pruritus score                        Study group\<Control group
  Study group (n=40): 1% phenol+1% menthol (BID)                                                                                     
  Control group (n=40): Placebo                                                                                                      
  Panahi^[@ref66]^                                                 6-week RDBCT                Pruritus score and DLQI               Improved by both regimens
  Study group (n=40): Doxepin cream 5% BID                                                                                           
  Control group (n=35): Beta. cream 0.1% BID                                                                                         
  Panahi^[@ref68]^                                                 6-week RDBCT                Pruritic score                        Study group=Control group
  Study group (n=31): Aloe vera/olive oil cream BID                Fissure, excoriation        Study group\<Control group            
  Control group (n=32): Beta. cream 0.1% BID                                                                                         
  Panahi^[@ref69]^                                                 4-week RDBCT                SCORAD                                Study group\<Control group
  Study group (n=20): IFN-gamma (50 µg/m2), SC, 3 times per week   DLQI                        Study group\<Control group            
  Control group (n=20): Beta. cream 0.1% daily                                                                                       
  Panahi^[@ref70]^                                                 6-week RDBCT                Pruritus score                        Study group=Control group
  Study group (n=35): Pimecrolimus cream 1% BID                                                                                      
  Control group (n=35): Beta. cream 0.1% BID                                                                                         
  Panahi^[@ref71]^                                                 6-week RDBCT                Pruritus, scaling, and skin dryness   Study group=Control group
  Study group (n=32): Capsaicin cream 0.025% BID                   Burning sensation           Not improved by capsaicin             
  Control group (n=32): Beta. cream 0.1% BID                                                                                         
  Shohrati^[@ref72]^                                               3-week RDBCT, 90 DCCS       Pruritus score                        Improved:
  Group 1 (n=30): Beta. %1 cream                                   Group 1=Group 2\>Group 3                                          
  Group 2 (n=30): Unna's Boot cream                                                                                                  
  Group 3 (n=30): Placebo cream                                                                                                      
  Shohrati^[@ref73]^                                               4-week RDBCT, DCCS          Pruritic score                        Improved
  Group 1: Cetirizine 10 mg/day                                    Group 3\>Group 2\>Group 1                                         
  Group 2: Doxepine 10 mg/day                                                                                                        
  Group 3: Hydroxyzine 25 mg/day                                                                                                     
  Shohrati^[@ref74]^                                               4-Week RDBCT, 50 DCCS       Pruritic score                        Improved
  Group 1 (n=25): Doxepine 10 mg/day                               Group 1=Group 2                                                   
  Group 2 (n=25): Hydroxyzine 25 mg/day                                                                                              

Beta.: Betamethasone; BID: Twice a day; DLQI: Dermatology life quality index; DCCS: Delay cutaneous complications of SM; RDBCT: Randomized double blinded clinical trial,; SC: Subcutaneously; SCORAD: Scoring atopic dermatitis

There is a positive correlation between concentrations of IFN-γ, TGF-beta and TNF-alpha, and pruritus severity.^[@ref67]^ The administration of subcutaneous IFN-γ (three times per week) was compared to the topical cream of betamethasone 0.1%. IFN-γ showed greater reductions in both atopic dermatitis score and dermatology life quality index (table 4). Patients complained of no major adverse effects from IFN-γ, and also researchers found no hematobiochemical abnormalities including markers of hematologic, renal, and hepatic functions.^[@ref69]^

The efficacy of cetirizine 10 mg/day, doxepine 10 mg/day, and hydroxyzine 25 mg/day, in relieving pruritus of DCCS patients, was evaluated in a 4-week double-blind clinical trial in Iranian SM veterans. All compounds reduced the pruritus scoring after one month; however, cetirizine showed lower effectiveness and sedation ([table 3](#T3){ref-type="table"}).^[@ref73]^

The combination of phenol 1% and menthol 1% reduced the skin pruritus of SM veterans significantly better than placebo ( [table 4](#T4){ref-type="table"}). However, the patients complained of its intolerable odor.^[@ref65]^

Skin dryness is one of DCCS that can be treated by soothing creams and emollients.3 Moreover, several compounds, as above-mentioned, were suggested for this purpose.^[@ref68],[@ref70],[@ref71],[@ref73]^

Dyspigmentation on non-covered areas, hands, and face leads to cosmetic problems in DCCS patients.^[@ref3],[@ref76]^ Sunscreen lotions or creams are recommended for hyper- and hypo-pigmentation areas.^[@ref3],[@ref77]^ Sunscreen protects hypopigmentation areas from UVA/UVB hazards secondary to inadequate amounts of melanin pigment. The combination of topical glucocorticoids, azelaic acid, hydroquinone, kojic acid, ascorbic acid, and tretinoin can be used to treat hyperpigmentation induced by SM.^[@ref3]^ Hypopigmentation, induced by SM, can be treated as for vitiligo by applying procedures such as ReCellÒ that inducts living and functional melanocytes and other skin cells.^[@ref3]^

As mentioned, for the management of respiratory complications, gamma interferon is also proposed for the management of SM skin complications considering its noticeable role of TGF-b in the pathogenesis of chronic inflammatory skin lesions of DCCS.^[@ref78]^

*Psychiatric and Social Problems of SM veterans* {#sec1-5}
------------------------------------------------

Since SM intoxication is a major stressor, some veterans suffer from PTSD (post-traumatic stress disorder). Physicians should continually assess the signs and symptoms of PTSD (e.g. obsessive-compulsive disorder, anxiety, somatization, depression, hostility).^[@ref3]^ A healthy lifestyle of the patients, appropriate financial/social/cultural support, reassurance, and supportive care are important in their clinical management.^[@ref1]^ Iranian veterans have benefited from social, financial, and cultural support including spiritual and religious practices.^[@ref79],[@ref80]^

Conclusion {#sec1-6}
==========

Various therapeutic methods for the clinical management of DCSM in Iranian veterans have been applied over the past few decades. Iranian researchers of various specialties (e.g. ophthalmologists, pulmonologists, and dermatologist), who have been involved in treating long-term effects and delayed complications of SM veterans, have recently published national treatment protocols. We have reviewed the recent advances of long-term treatment of delayed complications of SM poisoning including the protocols. It is concluded that the majority of treatments are still supportive and symptomatic. The veterans have benefited from a clinical management of different specialties based on the national treatment protocols.
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